Simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non-small cell lung cancer treated with intensity modulated radiotherapy

被引：6

作者：

Abe, Takanori ^{[1
]}

Iino, Misaki ^{[1
]}

Saito, Satoshi ^{[1
]}

Aoshika, Tomomi ^{[1
]}

Ryuno, Yasuhiro ^{[1
]}

Ohta, Tomohiro ^{[1
]}

Igari, Mitsunobu ^{[1
]}

Hirai, Ryuta ^{[1
]}

Kumazaki, Yu ^{[1
]}

Miura, Yu ^{[2
]}

Kaira, Kyoichi ^{[2
]}

Kagamu, Hiroshi ^{[2
]}

Noda, Shinei ^{[1
]}

Kato, Shingo ^{[1
]}

机构：

[1] Saitama Med Univ, Int Med Ctr, Dept Radiat Oncol, 1397-1 Yamane, Saitama 3501298, Japan

[2] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Saitama, Japan

来源：

THORACIC CANCER | 2022年 / 13卷 / 20期

关键词：

intensity modulated radiotherapy; locally-advanced lung cancer; lung dose optimization; SYMPTOMATIC RADIATION PNEUMONITIS; CONCURRENT CHEMORADIOTHERAPY; DURVALUMAB; CONSOLIDATION; THERAPY;

D O I：

10.1111/1759-7714.14634

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background In this study, we developed a simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non-small cell lung cancer (NSCLC) treated with intensity modulated radiotherapy (IMRT). Methods Data of 28 patients with stage IIB to IIIC NSCLC were retrospectively analyzed. All patients were treated with IMRT and a simulated three-dimensional conformal radiotherapy (3D-CRT) plan created for them. Dose-volume parameters of lung were analyzed for their correlation with radiation pneumonitis (RP). Results Over a median follow-up of 14 months, grade 1 pneumonitis was diagnosed in 14 patients (50%), grade 2 pneumonitis in 11 (39%), and grade 3 pneumonitis in one (4%). Two patients did not develop pneumonitis. None of the patients developed grade 4 or 5 pneumonitis. Regarding dose-volume parameter ratios between IMRT and simulated 3D-CRT, receiver operating characteristic analysis showed that mean lung dose (MLD)(IMRT)/MLD3D-CRT had the largest area under curve (0.750). Cumulative 6-month incidences of grade 2 or greater RP were 78.4% versus 19.5% (MLDIMRT/MLD3D-CRT, >= 1.0 or less); this difference was significant (p < 0.05). Conclusions We found that cutoff values for dose volume parameter ratios significantly predict grade 2 or greater RP. We believe that these parameter ratios could be useful in assisting evaluation of achievement degree of lung dose optimization in IMRT for LA-NSCLC.

引用

页码：2890 / 2896

页数：7

共 16 条

[1] Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer [J].

Abe, Takanori ;

Iino, Misaki ;

Saito, Satoshi ;

Aoshika, Tomomi ;

Ryuno, Yasuhiro ;

Ohta, Tomohiro ;

Igari, Mitsunobu ;

Hirai, Ryuta ;

Kumazaki, Yu ;

Miura, Yu ;

Kaira, Kyoichi ;

Kagamu, Hiroshi ;

Noda, Shin-ei ;

Kato, Shingo .

JOURNAL OF RADIATION RESEARCH, 2021, 62 (05) :894-900

[2] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[3]

Boyle J, 2017, ADV RADIAT ONCOL, V2, P6, DOI 10.1016/j.adro.2016.12.006

[4] Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial [J].

Chun, Stephen G. ;

Hu, Chen ;

Choy, Hak ;

Komaki, Ritsuko U. ;

Timmerman, Robert D. ;

Schild, Steven E. ;

Bogart, Jeffrey A. ;

Dobelbower, Michael C. ;

Bosch, Walter ;

Galvin, James M. ;

Kavadi, Vivek S. ;

Narayan, Samir ;

Iyengar, Puneeth ;

Robinson, Clifford G. ;

Wynn, Raymond B. ;

Raben, Adam ;

Augspurger, Mark E. ;

MacRae, RobertM. ;

Paulus, Rebecca ;

Bradley, Jeffrey D. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) :56-+

[5] Non-Small Cell Lung Cancer, Version 3.2022 [J].

Ettinger, David S. ;

Wood, Douglas E. ;

Aisner, Dara L. ;

Akerley, Wallace ;

Bauman, Jessica R. ;

Bharat, Ankit ;

Bruno, Debora S. ;

Chang, Joe Y. ;

Chirieac, Lucian R. ;

D'Amico, Thomas A. ;

DeCamp, Malcolm ;

Dilling, Thomas J. ;

Dowell, Jonathan ;

Gettinger, Scott ;

Grotz, Travis E. ;

Gubens, Matthew A. ;

Hegde, Aparna ;

Lackner, Rudy P. ;

Lanuti, Michael ;

Lin, Jules ;

Loo, Billy W. ;

Lovly, Christine M. ;

Maldonado, Fabien ;

Massarelli, Erminia ;

Morgensztern, Daniel ;

Ng, Thomas ;

Otterson, Gregory A. ;

Pacheco, Jose M. ;

Patel, Sandip P. ;

Riely, Gregory J. ;

Riess, Jonathan ;

Schild, Steven E. ;

Shapiro, Theresa A. ;

Singh, Aditi P. ;

Stevenson, James ;

Tam, Alda ;

Tanvetyanon, Tawee ;

Yanagawa, Jane ;

Yang, Stephen C. ;

Yau, Edwin ;

Gregory, Kristina ;

Hughes, Miranda .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (05) :497-530

[6] Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer [J].

Inoue, Hiroto ;

Ono, Akira ;

Kawabata, Takanori ;

Mamesaya, Nobuaki ;

Kawamura, Takahisa ;

Kobayashi, Haruki ;

Omori, Shota ;

Wakuda, Kazushige ;

Kenmotsu, Hirotsugu ;

Naito, Tateaki ;

Murakami, Haruyasu ;

Yasui, Kazuaki ;

Ogawa, Hirofumi ;

Onoe, Tsuyoshi ;

Endo, Masahiro ;

Harada, Hideyuki ;

Takahashi, Toshiaki .

INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) :1612-1617

[7] Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer [J].

Jung, Hyun Ae ;

Noh, Jae Myoung ;

Sun, Jong-Mu ;

Lee, Se-Hoon ;

Ahn, Jin Seok ;

Ahn, Myung-Ju ;

Pyo, Hongryull ;

Ahn, Yong Chan ;

Park, Keunchil .

LUNG CANCER, 2020, 146 :23-29

[8] Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy [J].

Koshy, Matthew ;

Malik, Renuka ;

Spiotto, Michael ;

Mahmood, Usama ;

Rusthoven, Chad G. ;

Sher, David J. .

LUNG CANCER, 2017, 108 :222-227

[9] Radiotherapy Patterns of Care for Locally-advanced Non-small Cell Lung Cancer in the Pre- and Post-durvalumab Era: A Region-wide Survey in a Japanese Prefecture [J].

Kubo, Nobuteru ;

Kobayashi, Daijiro ;

Iwanaga, Mototaro ;

Matsuura, Masana ;

Higuchi, Keiko ;

Eishima, Jun ;

Muramatsu, Hiroyuki ;

Okano, Naoko ;

Shioya, Mariko ;

Onishi, Masahiro ;

Aoki, Tetsuya ;

Oike, Takahiro ;

Ohno, Tatsuya .

JOURNAL OF RADIATION RESEARCH, 2022, 63 (02) :264-271

[10] Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer [J].

Mayahara, Hiroshi ;

Uehara, Kazuyuki ;

Harada, Aya ;

Kitatani, Keiji ;

Yabuuchi, Tomonori ;

Miyazaki, Shuichirou ;

Ishihara, Takeaki ;

Kawaguchi, Hiroki ;

Kubota, Hikaru ;

Okada, Hideaki ;

Ninomaru, Taira ;

Shindo, Chihiro ;

Hata, Akito .

RADIATION ONCOLOGY, 2022, 17 (01)

← 1 2 →